Table 1.

Details on participants N corresponds to the number of subjects per treatment type and phase. A few datasets were not available due technical problems and late withdrawals. Based on criteria specific to the present task (and not to the clinical trial), some subjects were excluded from the analysis ('excluded'). We report the age and sex of participants included in the analysis and the exact time of their test since the treatment onset.

DOI: http://dx.doi.org/10.7554/eLife.17282.007

Treatment type	Treatment phase	N not available	N excluded	N after exclusion	Sex (Male / female)	Age (years) ± SD of included subjects	Time since treatment onset (days) ± SD for included subjects
Placebo	Initial	0	5	27	14/13	23.4 ± 4.35	3.0 ± 0.68
Placebo	Intermediate	0	6	26	14/12	23.2 ± 4.33	13.8 ± 1.13
Placebo	Late	0	4	28	15/13	23.4 ± 4.27	54.7 ± 4.98
Escitalopram	Initial	1	8	23	11/12	24.5 ± 4.71	3.1 ± 0.63
Escitalopram	Intermediate	1	6	25	12/13	24.5 ± 4.51	14.0 ± 0.87
Escitalopram	Late	2	6	24	10/14	24.6 ± 4.61	55.3 ± 4.69